Promotional Claims. Impax shall limit the claims of efficacy and safety for the Product made by Impax Personnel to those which are consistent with (i) Wyeth’s approved labeling for the Product in the Territory and (ii) the Wyeth Sales Training Program. Impax shall not add, delete or modify claims of efficacy or safety in its Detailing of the Product nor make any changes in Promotion materials and literature provided by Wyeth. Impax’s Detailing of the Product shall be in strict adherence to all regulatory, professional and legal requirements including, without limitation, FDA’s regulations and guidelines concerning the advertising and promotion of prescription drug products, the American Medical Association’s Guidelines on Gifts to Physicians, the PhRMA Code on Interactions with Health Care Professionals, the ACCME Standards for Commercial Support of Continuing Medical Education, the Wyeth Policy on Sales and Marketing Practices, and any amendments or updates applicable to any of the foregoing. Upon notice to Impax of any breach of this Section 2.6.14, Impax shall ensure that there is no continuance of any such offending activity. Without limiting any other provision of this Agreement or any remedy Wyeth may have hereunder, any breach of the previous sentence or any intentional breach by Impax of the other provisions of this Section 2.6.14 by Impax shall constitute a material breach for the purposes of Section 9.2.
Promotional Claims. Sanofi and Relypsa each agree to [***] the claims of [***] for the Product made by the Parties’ respective PSRs and Sales Management Teams to those that are [***] for the Product in the Territory. Neither Party shall make any changes to the final Product Promotional and Educational Materials approved by the [***] pursuant to Section 3.3(a) above.
Promotional Claims. The general form of any promotional claims by HP regarding Aspect's Bispectral Index technology and/or the integration of this technology in HP Patient Monitors, and the specific form of the use of Aspect's trade names and trademarks, and of intended use claims regarding Aspect's Bispectral Index technology, in promotional material, advertisement, and/or in written technical literature shall be subject to review and approval by Aspect prior to its publication or display.
Promotional Claims. Each Party shall limit the claims of safety and efficacy that such Party or its sales force makes for a Product in the Copromotion Territory to those that are consistent with the approved labeling for such Product in such country of the Copromotion Territory. Neither Party may add, delete or modify claims of efficacy or safety in its Promotion of any Product in the Copromotion Territory nor make any changes in Promotion materials and literature approved by the MSC. Each Party's Detailing and Promotion of a Product in the Copromotion Territory shall be in strict adherence to all regulatory, professional and legal requirements including, without limitation, FDA's regulations and guidelines concerning the advertising of prescription drug products, the American Medical Association's Guidelines on Gifts to Physicians, the PhRMA Guidelines for Marketing Practices, the ACCME Standards for Commercial Support of Continuing Medical Education, the then current Copromotion Territory Commercialization Plan for the Product and any updates thereto.
Promotional Claims. The general form of any promotional claims by Marquette regarding Aspect's Bispectral Index technology and/or the integration of Aspect's Bispectral Index technology in Marquette Patient Monitors, and the specific form of the use of Aspect's trade names and trademarks, and of intended use claims regarding Aspect's Bispectral Index technology, in promotional material, advertisement, and/or in written technical literature shall be subject to review and approval by Aspect prior to its publication or display. The general form of any promotional claims by Aspect regarding Marquette's Patient Monitors or the integration of Aspect's Bispectral Index technology in Marquette Patient Modules, and the specific form of the use of Marquette's trade names and Trademarks, and of intended use claims regarding the Marquette BIS/EEG Modules, in promotional material, advertisement, and/or in written technical literature shall be subject to review and approval by Marquette prior to its publication or display.
Promotional Claims. ELAN shall limit the claims of safety and efficacy that ELAN or its sales force makes for a Collaboration Product in the Territory to those that are consistent with the approved labeling for such Collaboration Product in such country of the Territory. ELAN's detailing and promotion of a Collaboration Product in the Territory shall be in strict adherence to all regulatory, professional and legal requirements including, without limitation, FDA's regulations and guidelines concerning the advertising of prescription drug products and any updates thereto.
Promotional Claims. Sankyo sales representatives will not make any promotional claims for the Product not expressly approved by Cygnus.
Promotional Claims. 44 6.1.11 Samples................................................................................................ 44 6.1.12 Communications......................................................................................... 44 6.1.13 Training............................................................................................... 45 6.1.14 Compliance............................................................................................. 45 6.1.15
Promotional Claims. Each Party shall limit the claims of safety and efficacy that such Party or its sales force makes for VP Product to those that are consistent with the approved labeling for such VP Product in the Territory. Neither Party may add, delete or modify claims of efficacy or safety in its promotion of VP Product in the Territory nor make any changes in Promotional Materials created and approved in accordance with Section 5.11.1.
Promotional Claims. The general form of any promotional claims by Datascope regarding Aspect's Bispectral ASPECT / DATASCOPE OEM DEVELOPMENT AND PURCHASE AGREEMENT Index technology and/or the integration of Aspect's Bispectral Index technology in Datascope Patient Monitors, and the specific form of the use of Aspect's trade names and trademarks, and of intended use claims regarding Aspect's Bispectral Index technology, in promotional material, advertisement, and/or in written technical literature shall be subject to review and approval by Aspect prior to its publication or display. The general form of any promotional claims by Aspect regarding Datascope's Patient Monitors or the integration of Aspect's Bispectral Index technology in Datascope Patient Monitors, and the specific form of the use of Datascope's trade names and Trademarks, and of intended use claims regarding the Datascope [**] Systems, in promotional material, advertisement, and/or in written technical literature shall be subject to review and approval by Datascope prior to its publication or display.
